Muscle strength improvement — 12% gain in ATLAS RCT
The ATLAS trial (88 overweight middle-aged adults, 4 months, Cell Reports Medicine 2022) confirmed Urolithin A (Mitopure® 500–1,000 mg/day) significantly improved muscle strength by ~12% vs. placebo — one of the most compelling muscle health outcomes for a non-exercise intervention in aging populations. Additionally, clinically meaningful improvements in aerobic endurance (VO2) and physical performance (6-minute walk test) were observed.
Mitophagy activation — first human proof
The ATLAS trial was the first clinical study to demonstrate mitophagy activation in humans from a nutritional intervention — confirming that Urolithin A produces the cellular self-cleaning of dysfunctional mitochondria that has been the theoretical basis for its benefits. Muscle biopsy analysis showed a proteomic signature of improved mitochondrial metabolism and mitophagy gene expression, providing mechanistic validation for the functional benefits observed.
Muscle endurance in older adults (JAMA Network Open)
A separate double-blind RCT in adults aged 65–90 (JAMA Network Open 2022) confirmed Urolithin A (1,000 mg/day × 4 months) significantly improved muscle endurance in hand grip and leg muscles, improved 6-minute walk distance, and produced mitochondrial gene expression signatures consistent with mitophagy induction vs. placebo — establishing UA's benefits across both middle-aged and elderly populations.
Longevity pathway activation and healthy aging
Urolithin A activates multiple longevity-relevant pathways beyond mitophagy — including AMPK activation, SIRT1 induction, and NF-κB inhibition. Animal lifespan extension models consistently show extended healthspan with UA supplementation. The 25+ human studies from Amazentis/Timeline make Urolithin A one of the most extensively clinically validated longevity ingredients available.
Mitophagy activation via PINK1/Parkin pathway upregulation
Urolithin A activates mitophagy — the selective autophagy of dysfunctional mitochondria — by upregulating the PINK1/Parkin pathway that tags damaged mitochondria for degradation by autophagosomes. In aging muscle, defective mitochondria accumulate (mitochondrial dysfunction is a hallmark of aging) due to impaired mitophagy, reducing ATP production capacity and causing reactive oxygen species (ROS) accumulation. UA-induced mitophagy clears these defective mitochondria and triggers PGC-1α-mediated mitochondrial biogenesis to replace them with new, functional mitochondria — restoring the metabolic and contractile capacity that drives the strength and endurance improvements observed clinically.
Randomized, double-blind, placebo-controlled trial of Mitopure® 500 mg and 1,000 mg/day in 88 overweight middle-aged adults × 4 months. Published in Cell Reports Medicine 2022.
88 overweight middle-aged adults. 4-month RCT with muscle biopsy analysis.
Urolithin A ~12% improvement in muscle strength. Clinically meaningful improvements in VO2 and 6-minute walk test. First human proof of mitophagy activation from nutritional supplement. Mitochondrial proteomic improvements confirmed. Well-tolerated at both doses.
Double-blind, placebo-controlled RCT of Urolithin A (1,000 mg/day) in adults aged 65–90 × 4 months. Published in JAMA Network Open.
Adults aged 65–90. 4-month RCT at two medical centers.
Urolithin A significantly improved muscle endurance, 6-minute walk distance, and mitochondrial gene expression vs. placebo. Both hand grip and leg muscle endurance improved. Mitophagy biomarkers confirmed. Well-tolerated across aging population.